Virbac (ENXTPA:VIRP) is back in focus after its September 17 update, which paired its half year 2026 results with a guidance adjustment that now targets the upper end of its revenue growth range.
That guidance tweak lands against a mixed trading backdrop. Virbac’s 1-day share price return of 1.32% suggests the latest update has nudged sentiment. However, the 30-day and year to date share price returns, down 4.95% and 13.01% respectively, point to fading near term momentum, while a 3-year total shareholder return of 19.78% shows longer term holders have still seen a positive overall outcome.
Compare Virbac’s guidance shift with a curated set of established businesses with solid fundamentals through a similar lens in our list of solid balance sheet and fundamentals (202 results).
Virbac now trades at a steep discount to both its intrinsic estimate and analyst targets despite firmer revenue guidance. Does that gap signal an overdone market de rating or a fair price for higher uncertainty?
Most Popular Narrative: 26% Undervalued
Virbac's most followed valuation story points to a fair value of €412.88 against a last close of €307.50. This frames the current share price as materially below that narrative estimate and puts extra weight on the assumptions behind it.
The company is focused on increasing R&D investments to fuel a rich pipeline for future growth, targeting a ratio of 8.3% of revenue in 2025, which suggests future innovation and new product launches, impacting future revenue positively. The construction of new facilities, including a new biology site in Carros, a pet food facility in Nîmes, and a logistics center in Carros, aims to enhance operational capacity and efficiency, potentially improving gross margins and profitability.
See why 7 investors see Virbac as 26% undervalued.
Result: Fair Value of €412.88 (UNDERVALUED)
Still, Virbac’s heavier R&D spend and higher net debt from acquisitions could pressure earnings if new products or deals do not deliver as expected.
Find out about the key risks to this Virbac narrative.
Next Steps
Sentiment around Virbac is split, and that is exactly when it helps to dig into the numbers yourself and pressure test the story. If you want a quick snapshot of what the market is optimistic about, start with the 5 key rewards.
Looking for more Virbac investment ideas?
If you stop with Virbac, you only see part of the opportunity set. Broaden your watchlist now so you are not chasing ideas after they move.
- Target stability first and stress test your portfolio against a 221 resilient stocks with low risk scores that focuses on resilience when conditions change.
- Hunt for mispriced strength by scanning a 618 high quality undiscovered gems built around companies with robust fundamentals that the market may be overlooking.
- Lean into quality and potential upside by reviewing a 197 high quality undervalued stocks that filters for strong cash flows and solid balance sheets poised for a rerating.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com